The degradation of these driver proteins after HSP90 inhibition leads to loss of tumor cell viability [28], while decreased expression of the HSP90 gene is associated with increased survival of NSCLC patients [29]. This evidence concerns the gene HSP90AA1 and non-small cell lung carcinoma.